Amble Health vs MEDVi vs ShedRx (2026)

On tirzepatide, the order is ShedRx↗ ($289) → Amble Health ($300) → MEDVi↗ ($399) — gaps of $11 and then $99 a month, a $1,320 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

§ Each record, condensed

The three records, one screen

ShedRx: the record, condensed

ShedRx’s tirzepatide program bills $289 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Pricing steps with the dose here: from $199 at entry to $289 at the 10 mg basis. Multiply the wrong one of those by twelve and your budget is off by $1,080 a year, which is why every ranking on this site uses the larger number.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #5 of 17 in the verified tirzepatide index — $74/month above the floor (NexLife↗, $215) — and sits $160 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $3,468.

Start with the load-bearing figure: $249 a month, all-in, is what ShedRx charges for semaglutide at the 2.4 mg basis. The structure is tiered: the advertised entry point is $175, but the maintenance figure — the one a full year is actually billed at — is $249. That $74 gap between the ad and the anniversary is the single most important line in this record.

There is no membership line. $249 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #13 of 20 verified programs, with the floor $116/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $100 a month. A year at this figure: $2,988 monthly-billed.

Operationally at ShedRx: shipping included; commitment none month-to-month; cancellation 72-hour notice before the next billing cycle; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the ShedRx page · visit ShedRx ↗

Amble Health: the record, condensed

On tirzepatide, the number that matters at Amble Health is $300 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at Amble Health is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #9 of 17 in the verified tirzepatide index — $85/month above the floor (NexLife, $215) — and sits $149 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $3,600.

Operationally at Amble Health: shipping unknown; commitment unknown; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Amble Health page

MEDVi: the record, condensed

MEDVi’s tirzepatide program bills $399 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #14 of 17 verified programs, with the floor $184/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $50 a month. A year at this figure: $4,788 monthly-billed.

MEDVi’s semaglutide program bills $299 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at MEDVi is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

There is no membership line. $299 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #18 of 20 in the verified semaglutide index — $166/month above the floor (Oak Longevity, $133) — and sits $50 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $3,588.

Operationally at MEDVi: shipping included; commitment 12-month plan for the lowest rate; cancellation 12-month plan applies to lowest rate; pharmacy not publicly named — ask in writing before paying; states: priced differently in CA/NC on some plans; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the MEDVi page · visit MEDVi ↗

§ The three-way read

Prices, gaps, and what sits inside them

ShedRx holds the low ground at $289 with no membership attached. Amble Health follows at $300 (+$11/mo, $132/yr). MEDVi tops the trio at $399 (+$110/mo over the leader, $1,320/yr) — note its record’s watch-out below.

The semaglutide picture reshuffles nothing: ShedRx $249 → MEDVi $299 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.

§ Category winners among the three

Who wins what

Cheapest month-to-month: ShedRx ($289); cheapest 12-month path: ShedRx ($3,468); dose-flat structure: Amble Health and MEDVi; cheapest semaglutide of the three: ShedRx ($249).

Every winner above is a computation, not a placement; the pairwise pages carry the full duels: ShedRx vs Amble Health (record · record) · ShedRx vs MEDVi · Amble Health vs MEDVi (record · record).

§ Structure, three ways

Everything besides the three prices

Memberships: ShedRx none; Amble Health none; MEDVi none. Structures: ShedRx step/tiered; Amble Health dose-flat; MEDVi dose-flat. Pharmacies: ShedRx not named; Amble Health not named; MEDVi not named. States: ShedRx — not published; Amble Health — not published; MEDVi — priced differently in CA/NC on some plans. Exit terms: ShedRx — 72-hour notice before the next billing cycle; Amble Health — not published; MEDVi — 12-month plan applies to lowest rate.

The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: ShedRx source-verified (2026-08-05); Amble Health third-party reported (2026-08-05); MEDVi source-verified (2026-08-05).

The trio on semaglutide, across time

3 mo: ShedRx $747 vs MEDVi $897 6 mo: ShedRx $1,494 vs MEDVi $1,794 12 mo: ShedRx $2,988 vs MEDVi $3,588 — monthly-billed totals; prepaid paths where published appear on each provider page.

§ Twelve and twenty-four months

The trio, annualized

ShedRx: $3,468/yr monthly-billed; Amble Health: $3,600/yr monthly-billed; MEDVi: $4,788/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $2,640 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.

The elimination read

Work it as eliminations rather than a beauty contest. MEDVi enters owing an explanation: $110/month above ShedRx compounds to $1,320 a year — real therapy-months of money — so its record has to name what the premium buys (structure the cheaper two lack) or it exits first. Amble Health survives the first cut only to face the harder question — whether its dose-flat structure removes titration repricing is worth $11 a month to you — because a middle option that cannot answer it is just the expensive option with better camouflage. ShedRx is what remains: the arithmetic answer at $289, dethroned only by a state gap, a structural need, or a prescriber’s judgment — the three things this page deliberately cannot decide.

The same trio on best published rate: ShedRx $289 → Amble Health $300 → MEDVi $399 — all three price month-to-month only at capture. Short-horizon totals, monthly-billed: 3 months — ShedRx $867, Amble Health $900, MEDVi $1,197; 6 months — ShedRx $1,734, Amble Health $1,800, MEDVi $2,394. 0 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.

Grade the three records before trusting the three prices. On the five-point disclosure checklist (price, pharmacy, states, cancellation, source-verification): ShedRx 4/5 · Amble Health 3/5 · MEDVi 4/5. The gap between ShedRx (4/5) and Amble Health (3/5) is itself information: undisclosed axes are where the questions in each provider’s review earn their keep. No axis splits them, a small collective credit. Every score is a computation from the dataset, contestable at the corrections desk like any other figure.

The three-way verdict compresses cleanly: ShedRx is the default on arithmetic; Amble Health earns the middle only where its structure (flat pricing) solves something the floor does not; and MEDVi’s $110/month premium over the leader — $1,320 a year, roughly 4.6 extra months of therapy at the floor rate — needs a named justification from its record, not a vibe. Insurance coverage, where it exists, outranks all three.